Bio-Rad Laboratories, Inc. Class A Common Stock vs Costco Wholesale Corporation — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $356.44 (market cap $9.39B), while Costco Wholesale Corporation trades at $942.01 (market cap $422.52B). The key difference: Costco Wholesale Corporation is far larger — about 45× Bio-Rad Laboratories, Inc. Class A Common Stock's market cap, and Costco Wholesale Corporation pays a 0.62% dividend while Bio-Rad Laboratories, Inc. Class A Common Stock pays none. Which is the better fit depends on your goals.
| BIO | COST | |
|---|---|---|
Market Cap | $9.39B | $422.52B |
Sector | Health | Consumer Staples |
52-Week High | $356.25 | $1.09K |
52-Week Low | $241.71 | $849.63 |
Enterprise Value | $9.14B | $410.66B |
Dividend Yield | — | 0.62% |
Signals from Pluang's Aura AI — not financial advice
BIO trades at $352.47, up 2.93% today, near its consensus price target of $350. The stock shows a bullish technical trend with strong moving average signals, though RSI levels indicate overbought conditions. Fundamentally, Q2 2026 earnings beat expectations at $2.62 EPS, but revenue remains flat at $2.58 billion in 2025. The company has returned to profitability with a net income of $759.9 million after losses in prior years, supported by a solid gross margin of 51.9%.
The outlook is cautiously optimistic with analyst consensus at Buy (53.85%), but high P/E of 43.18 suggests premium valuation. Risks include revenue stagnation and sensitivity to academic research funding. Upside is supported by positive cash flow trends and institutional accumulation, yet investors should weigh valuation against growth prospects.
Costco (COST) trades at $952.75, up 0.52% with neutral technical signals. The company shows steady revenue growth, reaching $275.24B in 2025, and maintains strong profitability with a 3.01% net margin. Recent earnings beat expectations in Q3 and Q4 2025 but missed in Q1 2026. Analyst sentiment remains bullish with 65.52% buy ratings and a $1,120 consensus price target, while institutional buying activity continues.
Costco's outlook is positive due to membership fee growth and expansion, though high valuation multiples (P/E 47.93) pose risks. Key opportunities include consistent cash flow generation and market share gains, while risks involve competitive pressures and economic sensitivity. The stock offers long-term growth potential but requires monitoring of valuation metrics.
Trailing returns across standard periods
Latest headlines on both assets
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →The leading warehouse club, Costco has 815 stores worldwide (at the end of fiscal 2021), with most sales derived in the United States (72%) and Canada (14%). It sells memberships that allow customers to shop in its warehouses, which feature low prices on a limited product assortment. Costco mainly caters to individual shoppers, but roughly 20% of paid members carry business memberships. Food and sundries accounted for 40% of fiscal 2021 sales, with non-food merchandise 29%, warehouse ancillary and other businesses (such as fuel and pharmacy) nearly 17%, and fresh food 14%. Costco's warehouses average around 146,000 square feet
Read more on COST →